Research analysts at Leerink Partnrs raised their Q1 2025 earnings estimates for shares of Nkarta in a research report issued ...

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on March 27. The company’s shares closed ...

Leerink Partnrs lowered shares of Equillium (NASDAQ:EQ – Free Report) from a strong-buy rating to a hold rating in a research report released on Friday,Zacks.com reports. Leerink Partnrs also issued ...

Fintel reports that on March 28, 2025, Leerink Partners downgraded their outlook for Equillium (NasdaqCM:EQ) from Outperform ...

The resignation of one of the FDA's top officials, Peter Marks, is worrying Wall Street as they await a replacement.

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

Biotech stocks plunge after Dr. Peter Marks resigns from FDA, citing disputes with RFK Jr. over vaccines and drug approvals.

Fintel reports that on March 25, 2025, Leerink Partners downgraded their outlook for Opthea Limited - Depositary Receipt () ...

Shares of Moderna, Novavax and other biotech companies fell after FDA official Peter Marks’s resignation in protest of Robert ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Shares in Moderna, Vaxcyte, Novavax and BioNTech all fell Monday after Peter Marks, head of the FDA office that reviews ...

Leerink analyst Thomas Smith downgraded Equillium (EQ) to Market Perform from Outperform with a price target of $1, down from $3. The company ...